Brief: Guerbet Q3 Revenue Up At EUR 187 Mln
Oct 20 (Reuters) - GUERBET SA GRBT.PA :
* 2022 FINANCIAL OBJECTIVES UPDATE
* IMPACT OF THE PRIORITIZATION OF ELUCIREMTM PRODUCTION ON
THE
RALEIGH SITE
* 2022 OUTLOOK: REVENUE GROWTH OF LESS THAN 2% AT SCOPE AND
CER
* 2022 OUTLOOK: EBITDA MARGIN BETWEEN 13 AND 14%
* Q3 REVENUE: +5.1% AT CONSTANT EXCHANGE RATES (€187M)
Source text for Eikon: ID:nGNX9hhtKT
Further company coverage: GRBT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))
Recent news on Guerbet SA
See all newsBrief: Guerbet Q1 Revenue At EUR 177.4 Mln
Guerbet Q1 revenue up 2.6% at CER on increased volumes in EMEA and Asia
Medical imaging firm Guerbet's 2025 revenue falls on lower sales activity in France
Brief: Guerbet Says FDA Approves Labeling Update For Guerbet's Elucirem Injection
France's Guerbet misses 2025 revenue estimates